Accueil › Cancer métastatique › Kentucky › Lexington
Essais cliniques pour Cancer métastatique à Lexington, KY
11 études pour Cancer métastatique recherchent des participants dans et autour de Lexington (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Recrutement en coursPhase 2
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Recrutement en coursPhase 1
- University of Kentucky/Markey Cancer Center, Lexington
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Recrutement en coursPhase 2/3
- University of Kentucky Markey Cancer Center, Lexington
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Recrutement en coursPhase 3
- Baptist Health Lexington, Lexington
- Baptist Health Richmond, Lexington
- Baptist Health Hamburg, Lexington
- et 3 autres
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Recrutement en coursPhase 2/3
- University of Kentucky Research Foundation, Lexington
- University of Kentucky Healthcare - Markey Cancer Center, Lexington
- University of Kentucky Medical Center, Lexington
- et 1 autres
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Recrutement en coursPhase 3
- Baptist Health Lexington, Lexington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Recrutement en coursPhase 2
- University of Kentucky/Markey Cancer Center, Lexington
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Recrutement en coursPhase 1/2
- Crinetics Study Site, Lexington
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Recrutement en coursPhase 1
- UK Markey Cancer Center, Lexington
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Recrutement en coursPhase 1
- University of Kentucky Markey Cancer Center, Lexington
Essais pour Cancer métastatique dans d'autres villes
- Houston, TX104 études
- New York City, NY93 études
- Nashville, TN70 études
- Boston, MA63 études
- Los Angeles, CA57 études
- St. Louis, MO54 études
- Arlington, VA53 études
- Philadelphia, PA46 études
- Chicago, IL45 études
- San Antonio, TX44 études
- Washington, DC43 études
- Dallas, TX42 études
Autres études à Lexington
- Cancer du poumon non à petites cellules23 études
- Cancer du poumon18 études
- Cancer de l'ovaire16 études
- Cancer de la prostate14 études
- Cancer (tous types)14 études
- Cancer du sein14 études
- Cancer colorectal11 études
- Insuffisance cardiaque11 études
- Mélanome10 études
- Leucémie aiguë myéloïde10 études
- Obésité10 études
- Carcinome épidermoïde de la tête et du cou9 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.